Literature DB >> 29669965

Serum adropin levels are decreased in Chinese type 2 diabetic patients and negatively correlated with body mass index.

Huanhuan Zang1, Fusong Jiang2, Xingbo Cheng1, Hong Xu1, Xingna Hu1.   

Abstract

Adropin has been identified as potent regulatory hormone implicated in insulin sensitivity and the maintenance of energy homeostasis. The aim of current study was to investigate serum adropin concentrations of type 2 diabetes mellitus (T2DM) patients in the fasting status, especially those overweight/obese and evaluate the relationships between adropin levels and metabolic parameters. A total of 116 T2DM patients and 60 controls with normal glucose tolerance (NGT) were recruited to the study. Adropin concentration was determined using commercial ELISA kits. Anthropometric characteristics were collected and biochemistry, glycosylated hemoglobin A1c (HbA1c) and fasting insulin (FIns) were detected by clinical laboratory. Insulin resistance was estimated by homeostasis model 2 assessment of insulin resistance (HOMA2-IR). Serum adropin levels in Chinese T2DM patients were decreased compared with the controls [3.8 (3.0-5.5) vs. 5.5 (3.7-7.9) ng/mL, p < 0.01]. Meanwhile, overweight/obese patients had more considerably reduced levels of adropin. Adropin level was negatively correlated with body mass index (BMI), high-sensitive C reactive protein (hs-CRP), triglycerides (TG), fasting plasma glucose (FPG), FIns, HOMA2-IR and HbA1c, while positively with high-density lipoprotein cholesterol (HDL-C) in study participants (p < 0.01). The correlations of adropin with glucolipid variables (TG, HDL-C, FPG, FIns, HOMA2-IR, HbA1c) still existed after adjusting the effect of BMI. Besides, HOMA2-IR and HbA1c were independent factors associated with serum adropin levels. Binary logistic regression analyses showed that adropin was significantly associated with T2DM after removing confounding factors (p < 0.01). Receiver operating characteristic (ROC) curve demonstrated adropin concentration of 5.8 ng/mL could be used as a possible optimal cut-off value to identify T2DM from non-T2DM with sensitivity of 81.9% and specificity of 46.7%. Serum adropin concentrations are decreased in Chinese T2DM patients, especially those overweight/obese. Adropin, associated with glucolipid homeostasis and insulin sensitivity, may implicate in the pathogenesis of T2DM.

Entities:  

Keywords:  Adropin; Insulin resistance; Obesity; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29669965     DOI: 10.1507/endocrj.EJ18-0060

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  19 in total

1.  Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction.

Authors:  Subhashis Banerjee; Sarbani Ghoshal; Joseph R Stevens; Kyle S McCommis; Su Gao; Mauricio Castro-Sepulveda; Maria L Mizgier; Clemence Girardet; K Ganesh Kumar; Jose E Galgani; Michael L Niehoff; Susan A Farr; Jinsong Zhang; Andrew A Butler
Journal:  J Biol Chem       Date:  2020-07-29       Impact factor: 5.157

2.  Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates.

Authors:  Andrew A Butler; Jinsong Zhang; Candice A Price; Joseph R Stevens; James L Graham; Kimber L Stanhope; Sarah King; Ronald M Krauss; Andrew A Bremer; Peter J Havel
Journal:  J Biol Chem       Date:  2019-04-15       Impact factor: 5.157

Review 3.  Correlation Between Circulating Adropin Levels and Patients with PCOS: An Updated Systematic Review and Meta-analysis.

Authors:  Yani Ke; Jie Hu; Yuqing Zhu; Yaqin Wang; Shuaihang Chen; Shan Liu
Journal:  Reprod Sci       Date:  2022-01-11       Impact factor: 3.060

4.  Adropin transgenesis improves recognition memory in diet-induced obese LDLR-deficient C57BL/6J mice.

Authors:  Sarbani Ghoshal; Subhashis Banerjee; Jinsong Zhang; Michael L Niehoff; Susan A Farr; Andrew A Butler
Journal:  Peptides       Date:  2021-10-22       Impact factor: 3.750

5.  Promotion of Adropin Expression by Hyperglycemia Is Associated with STAT3 Activation in Diabetic Rats.

Authors:  Feng Yu Kuo; Kai-Chun Cheng; Yingxiao Li; Juei-Tang Cheng; Cheng-Chia Tsai
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-29       Impact factor: 3.168

6.  Association of retinol binding protein-4, cystatin C, homocysteine and high-sensitivity C-reactive protein levels in patients with newly diagnosed type 2 diabetes mellitus.

Authors:  Yun-Sheng Wang; Jun Ye; Xiao Yang; Gui-Ping Zhang; Yong-Hong Cao; Rong Zhang; Wu Dai; Qiu Zhang
Journal:  Arch Med Sci       Date:  2018-11-13       Impact factor: 3.318

Review 7.  The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Adipose Tissue Functions.

Authors:  Paweł A Kołodziejski; Ewa Pruszyńska-Oszmałek; Tatiana Wojciechowicz; Maciej Sassek; Natalia Leciejewska; Mariami Jasaszwili; Maria Billert; Emilian Małek; Dawid Szczepankiewicz; Magdalena Misiewicz-Mielnik; Iwona Hertig; Leszek Nogowski; Krzysztof W Nowak; Mathias Z Strowski; Marek Skrzypski
Journal:  Genes (Basel)       Date:  2021-05-17       Impact factor: 4.096

8.  Adropin Slightly Modulates Lipolysis, Lipogenesis and Expression of Adipokines but Not Glucose Uptake in Rodent Adipocytes.

Authors:  Mariami Jasaszwili; Ewa Pruszyńska-Oszmałek; Tatiana Wojciechowicz; Mathias Z Strowski; Krzysztof W Nowak; Marek Skrzypski
Journal:  Genes (Basel)       Date:  2021-06-13       Impact factor: 4.096

9.  Serum adropin levels are reduced in patients with inflammatory bowel diseases.

Authors:  Darko Brnić; Dinko Martinovic; Piero Marin Zivkovic; Daria Tokic; Ivana Tadin Hadjina; Doris Rusic; Marino Vilovic; Daniela Supe-Domic; Ante Tonkic; Josko Bozic
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

10.  Plasma Adropin as a Potential Marker Predicting Obesity and Obesity-associated Cancer in Korean Patients With Type 2 Diabetes Mellitus.

Authors:  Ha-Neul Choi; Jung-Eun Yim
Journal:  J Cancer Prev       Date:  2018-12-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.